Risk of Breast Cancer and Breast Cancer Characteristics in Women Treated With Supradiaphragmatic Radiation for Hodgkin Lymphoma: Mayo Clinic Experience

Wahner-Roedler, Dietlind L.; Nelson, Diana F.; Croghan, Ivana T.; Achenbach, Sara J.; Crowson, Cynthia S.; Hartmann, Lynn C.; O'Fallon, W. Michael
June 2003
Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p708
Academic Journal
• Objective: To evaluate the overall risk of breast cancer and breast cancer characteristics in women given supradiaphragmatic radiation therapy for Hodgkin lymphoma. • Patients and Methods: Medical records of 653 female patients who received supradiaphragmatic radiation therapy for Hodgkin lymphoma at the Mayo Clinic in Rochester, Minn, between 1950 and 1993 were abstracted, and follow-up questionnaires were mailed. In 4 patients, breast cancer was diagnosed before Hodgkin lymphoma was discovered. • Results: The median age of 649 patients at supradiaphragmatic radiation therapy was 31.8 years (range, 2.6-86.5 years). The median duration of follow-up was 8.7 years (range, <1-47.9 years). In 30 patients, breast cancer developed (bilaterally in 4 patients) after supradiaphragmatic radiation therapy; the median interval was 19.9 years (range, 0.7-42.3 years). The median age at breast cancer diagnosis was 44.4 years (range, 27.5-70.8 years). The standardized morbidity ratio for breast cancer after supradiaphragmatic radiation therapy was 2.9 (95% confidence interval [CI], 2.0-4.2) (P<.001). Breast cancer risk significantly increased 15 to 30 years after patients received supradiaphragmatic radiation therapy, and risk was inversely related to age at supradiaphragmatic radiation therapy until age 30 years. The standardized morbidity ratio for patients younger than 30 years at supradiaphragmatic radiation was 8.5 (95% CI, 5.3-13.1) vs 1.2 (95% CI, 0.5-2.2) for those aged 30 years or older (P<.001). Splenectomy increased breast cancer risk (P=.01). Breast cancer detection was by self-examination in 15 cancers, by mammography in 13, and by clinical examination in 4; in 2 cancers, the mode of detection was unknown. Modified radical mastectomy was used to treat breast cancer. • Conclusion: The increased risk of breast cancer in survivors of Hodgkin lymphoma given supradiaphragmatic radiation therapy appears to be limited to patients who are younger than 30 years at radiation therapy or to those who have undergone splenectomy.


Related Articles

  • Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.  // Current Medical Literature: Leukemia & Lymphoma;2012, Vol. 20 Issue 3, p106 

    The author comments on the paper "Breast cancer risk after supradiaphragmatic radiotherapy (RT) for Hodgkin's lymphoma in England and Wales: a National Cohort Study," by A. J. Swerdlow and colleagues. The author claims the research clarifies that a substantial and significant risk is conferred...

  • Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. Cooke, R; Jones, M E; Cunningham, D; Falk, S J; Gilson, D; Hancock, B W; Harris, S J; Horwich, A; Hoskin, P J; Illidge, T; Linch, D C; Lister, T A; Lucraft, H H; Radford, J A; Stevens, A M; Syndikus, I; Williams, M V; Swerdlow, A J // British Journal of Cancer;6/11/2013, Vol. 108 Issue 11, p2399 

    Background:Women treated with supradiaphragmatic radiotherapy (sRT) for Hodgkin lymphoma (HL) at young ages have a substantially increased breast cancer risk. Little is known about how menarcheal and reproductive factors modify this risk.Methods:We examined the effects of menarcheal age,...

  • Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Dores, G. M.; Anderson, W. F.; Beane Freeman, L. E.; Fraumeni, J. F.; Curtis, R. E.; Fraumeni, J F Jr // British Journal of Cancer;9/28/2010, Vol. 103 Issue 7, p1081 

    Background: It is unknown whether breast cancer (BC) characteristics among young women treated with radiotherapy (RT) for Hodgkin's lymphoma (HL) differ from sporadic BC.Methods: Using population-based data, we calculated BC risk following HL according to...

  • Breast cancer in women following mantle irradiation for Hodgkin's disease. Peters, Mark H.; Sonpal, Indukumar M. // American Surgeon;Sep1995, Vol. 61 Issue 9, p763 

    Discusses previous studies on the incidence of breast cancer in women after receiving mantle radiation therapy for Hodgkin's disease. Factors contributing to the incidence of breast cancer; Need for a vigilant screening routine for old patient which undergone mantle radiation therapy; Need to...

  • Risk - Recurrence or Contralateral Disease.  // Current Medical Literature: Breast Cancer;2010, Vol. 22 Issue 1, p24 

    The article presents an evaluation performed on female over 18 years old on how disseminated tumor cells (DTCs) and the threat of locoregional recurrence (LRR) in non-metastatic breast cancer is influenced by adjuvant locoregional radiotherapy. It offers an analysis of how isoflavones, found in...

  • Breast Cancer After Hodgkin Disease: Hope for a Safer Cure. Yahalom, Joachim // JAMA: Journal of the American Medical Association;7/23/2003, Vol. 290 Issue 4, p529 

    Editorial. Multiple studies have documented the risk of breast cancer after Hodgkin disease (HD). The increased risk of breast cancer is associated with radiotherapy. The risk is age-related, with highest risk linked to treatment at age ten to 20 years. The median time from HD treatment to...

  • Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer. Vodusek, Ana Lina; Novakovic, Srdjan; Stegel, Vida; Jereb, Berta // Radiology & Oncology;2011, Vol. 45 Issue 4, p296 

    Background. Some tumour suppressor genes (BRCA2) and mismatch repair genes (MSH2, MLH1) are correlated with an increased risk for male breast cancer. Case report. Our patient developed secondary breast cancer after the treatment for Hodgkin's disease in child- hood. DNA was isolated from the...

  • Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease. Travis, Lois B.; Hill, Deirdre A.; Dores, Graça M.; Gospodarowicz, Mary; van Leeuwen, Flora E.; Holowaty, Eric; Glimelius, Bengt; Andersson, Michael; Wiklund, Tom; Lynch, Charles F.; Van't Veer, Mars B.; Glimelius, Ingrid; Storm, Hans; Pukkala, Eero; Stovall, Marilyn; Curtis, Rochelle; Boice, Jr, John D.; Gilbert, Ethel // JAMA: Journal of the American Medical Association;7/23/2003, Vol. 290 Issue 4, p465 

    Context: Second cancer is the leading cause of death in long-term survivors of Hodgkin disease (HD), with exceptionally high risks of breast cancer among women treated at a young age. Quantitative associations between radiotherapy dose delivered to the breast and administered chemotherapy have...

  • THIS WEEK IN JAMA. Meyer, Catherine // JAMA: Journal of the American Medical Association;7/23/2003, Vol. 290 Issue 4, p435 

    The topics of medical research appearing in this issue of "JAMA" include long-term risk of breast cancer in Hodgkin disease, cancer and mortality risk with antioxidant supplements, acarbose therapy and risk for cardiovascular disease in patients with impaired glucose tolerance, failure to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics